Eisai Co Ltd (4523.T)
17 Aug 2018
Fri, Aug 17 2018
(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)
CORRECTED-(OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)
* Wholesale price before discount is $16,970 for a 30-day supply
Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.
TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)
CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.
July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.
* Says it forms business and capital alliance with Eisai Co Ltd
BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan
* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC
(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)
* Eisai's drug Lenvima already approved in dozens of countries